As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

Growth stocks are equity shares likely to outperform their peers and the broader market. Here's a list of stocks that contain ...

"An MDL that encompassed any potential injury relating to use of these exceedingly popular weight loss drugs might quickly ...

With U.S. headquarters in Plainsboro, Novo Nordisk told NJBIZ, "NAION is a very rare eye disease, and it is not an adverse ...

Viking Therapeutics shows promise with weight loss drug VK2735 and potential in NASH treatment, making it a potential ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Eli Lilly & Co.’s diabetes and weight-loss drugs Mounjaro and Zepbound are no longer in short supply in the US, which means ...

Among the products that Nestle is producing include protein-based pasta, sandwiches, and pizza, as well as whole grain-filled frozen bowls. The items are expected to be priced at $4.99 or lower and ...

That's why Novo Nordisk's shares are worth sticking with for good, and at about $108 apiece, investors can afford two of them ...